GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » ROC (Joel Greenblatt) %
中文

GlycoMimetics (GlycoMimetics) ROC (Joel Greenblatt) % : -4,133.62% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. GlycoMimetics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,133.62%.

The historical rank and industry rank for GlycoMimetics's ROC (Joel Greenblatt) % or its related term are showing as below:

GLYC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5171.17   Med: -2882.72   Max: -1520.56
Current: -4187.1

During the past 13 years, GlycoMimetics's highest ROC (Joel Greenblatt) % was -1520.56%. The lowest was -5171.17%. And the median was -2882.72%.

GLYC's ROC (Joel Greenblatt) % is ranked worse than
84.62% of 1469 companies
in the Biotechnology industry
Industry Median: -339.22 vs GLYC: -4187.10

GlycoMimetics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -4.90% per year.


GlycoMimetics ROC (Joel Greenblatt) % Historical Data

The historical data trend for GlycoMimetics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics ROC (Joel Greenblatt) % Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,565.36 -1,520.56 -2,594.44 -3,516.54 -5,171.17

GlycoMimetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,240.32 -5,898.11 -3,429.67 -3,220.34 -4,133.62

Competitive Comparison of GlycoMimetics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, GlycoMimetics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's ROC (Joel Greenblatt) % falls into.



GlycoMimetics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.413) - (3.243 + 0 + 2.398)
=-3.228

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.822) - (3.132 + 0 + 2.961)
=-4.271

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of GlycoMimetics for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-38.36/( ( (1.088 + max(-3.228, 0)) + (0.768 + max(-4.271, 0)) )/ 2 )
=-38.36/( ( 1.088 + 0.768 )/ 2 )
=-38.36/0.928
=-4,133.62 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlycoMimetics  (NAS:GLYC) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


GlycoMimetics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (GlycoMimetics) Business Description

Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
Executives
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950